In today's clinical practice, there is no appropriate "one size fits all" treatment approach for COPD. But while this progressive trend toward personalized medicine standards helps optimize COPD care for each patient, the cost-to-benefit ratio for drug development changes as COPD evolves from one disease state into a larger disease spectrum. What is the current to future pipeline for drug R&D in the COPD arena, and is the horizon optimistic for delivering better treatment methods to patients? Joining Dr. Matt Birnholz to discuss the "Pulmonary Pipeline" is Dr. Nicholas Gross, pulmonologist and industry news reporter. Dr. Gross is emeritus professor of medicine and molecular biology at Loyola University in Chicago.
